Hepatitis B core protein inhibitor, ABI-H0731, produces promising results in Phase 2a studies
ILC 2019: Interim data from two Phase 2a studies of ABI-H0731 suggest good tolerability and enhanced antiviral efficacy in combination with standard-of-care in chronic hepatitis B infection 13 April 2019,…
Calmangafodipir may reduce liver injury after paracetamol overdose: final results from the POP trial
ILC 2019: Phase 1 study demonstrates that superoxide dismutase mimetic, calmangafodipir, is well tolerated and may reduce liver injury after paracetamol overdose 12 April 2019, Vienna, Austria EASL (EUROPEAN ASSOCIATION…
Nonalcoholic fatty liver disease found in large numbers of teenagers and young adults: is a public health crisis looming?
ILC 2019: UK population-based study finds large numbers of young adults have nonalcoholic fatty liver disease (NAFLD) and many of these already have fibrosis 12 April 2019, Vienna, Austria EASL…
Glecaprevir/pibrentasvir (G/P) is effective and well tolerated in large ‘real-world’ studies in individuals with hepatitis C virus (HCV) infection
ILC 2019: German and US studies confirm the efficacy and safety of G/P in a broad range of individuals with HCV infection and other comorbidities, showing improvements in mental and…
MSDC-0602K shows potential for improving markers of liver disease in individuals with nonalcoholic steatohepatitis (NASH)
ILC 2019: Second-generation thiazolidinedione, MSDC-0602K may significantly improve liver enzymes, fibrosis, and glycaemic markers with minimal adverse events, according to a Phase 2b study 12 April 2019, Vienna, Austria EASL…